EPL and Aclairo Combine Preclinical Services Expertise
EPL is pleased to announce that it has acquired Aclairo Pharmaceutical Development Group, Inc. (Aclairo) which provides independent and objective nonclinical, regulatory, and clinical ADME/DMPK expert strategy and implementation to the pharmaceutical and drug device industries.
“Aclairo’s team of industry and ex-FDA experts have developed a specialized consultancy in drug and device development strategy with breadth and depth in the biologic, pharmaceutical and device arenas. Their expertise includes regulatory strategy and oversight, pharmacology, toxicology, DMPK, and overall program design, placement, management and interpretation.” said Dr. Jerry Hardisty, EPL’s President and CEO.
“EPL and Aclairo share a similar market and are focused on providing a tailored solution for each client. The combination of each organization’s strengths will help deliver a more comprehensive product for our clients.”
Aclairo has been committed for more than a decade to delivering independent and objective nonclinical, regulatory, and clinical DMPK advice to the pharmaceutical, biologics, and device industry. Aclairo is a wholly owned subsidiary of EPL and is located in Vienna, VA.
More information about Aclairo can be found at www.aclairo.com.
Categories: NewsTags: Aclairo, ADME, biologics, DMPK, drug development, EPL, Jerry Hardisty, Medical Devices, nonclinical, pharmaceuticals, pharmacology, Preclinical services, regulatory strategy, Toxicology